MicroRNA-10b与早期乳腺浸润性导管癌的临床及预后研究

目的  探讨早期乳腺浸润性导管癌中microRNA-10b（miR-10b）表达与临床指标及预后关系。 方法  采用原位分子杂交技术，检测305例中早期乳腺浸润性导管癌组织miR-10b表达，采用Pearsonχ2检验分析miR-10b表达在不同临床指标间的差异性；采用Spearman秩和相关分析早期乳腺浸润性导管癌中miR-10b、年龄、淋巴结、雌激素受体α（ERα）、孕激素受体（PR）及人类表皮生长因子受体2（HER-2）之间的相关性。采用Kaplan-Meier法计算累计无瘤生存时间，应用Log-rank检验比较miR-10b不同表达组间无瘤生存时间的差异。结果  早期乳腺浸润性导管癌中miR-10b表达与年龄、肿瘤大小和复发转移，差异具有统计学意义（P <0.05）；与月经状态、临床分期、化疗、放疗及内分泌治疗比较，差异无统计学意义（P >0.05）。miR-10b阳性表达与HER-2阳性表达呈正相关，差异有统计学意义（P <0.05）。miR-10b表达阴性中位无瘤生存时间较miR-10b表达阳性时间长，两者比较差异有统计学意义（P <0.05）；淋巴结阴性时miR-10b阴性表达的中位无瘤生存时间较阳性表达长，两者比较差异有统计学意义（P <0.05）；相反，miR-10b表达在淋巴结阳性中位无瘤生存时间无统计学意义（P >0.05）。结论  miR-10b表达水平与早期乳腺浸润性导管癌复发转移相关，特别在无淋巴结转移且miR-10b阳性表达组的中位无瘤生存时间短，预后差。miR-10b阳性表达是早期乳腺浸润性导管癌的预后因素。

Relationships of miR-10b expression with clinical parameters and prognosis in patients with early breast invasive ductal carcinoma

Objective To discuss the reationships of clinical parameters and prognosis of early breast invasive ductal carcinoma with miRNA-10b (miR-10b) expression. Methods In situ molecular hybridization technique was used to detect miR-10b expression in early breast invasive ductal cancer tissues of 305 cases. Pearson Chi-square test was adopted to analyze the differences in miR-10b expression between the patients with different clinical indicators. Spearman rank test was used to analyze the correlations of miR-10b expression with age, lymph node metastasis, estrogen receptor α (ERα), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) in early breast invasive ductal cancer. Kaplan-Meier method was adopted to calculate the accumulative tumor-free survival time. Log-rank test was applied to compare the tumor-free survival time between the groups with different miR-10b expressions. Results There were significant differences in age, tumor recurrence and metastasis between the early breast invasive ductal cancer patients with different miR-10b expressions (P < 0.05); however, there was no significant difference in menstrual status, clinical stage, chemotherapy, radiotherapy or endocrine therapy (P > 0.05). Positive miR-10b expression was positively correlated with positive HER-2 expression (P < 0.05). The median survival time of the patients with negative miR-10b expression was significantly longer than that of the patients with positive miR-10b expression (P < 0.05). When there was no lymph node metastasis, the median tumor-free survival time of the patients with negative miR-10b expression was significantly longer than that of the patients with positive miR-10b expression (P < 0.05); while there was no statistical difference in the median tumor-free survival time when there was lymph node metastasis (P > 0.05). Conclusions miR-10b expression level is associated with recurrence and metastasis of early breast invasive ductal carcinoma, especially in the absence of lymph node metastasis; and in the miR-10b positive expression group the median tumor-free survival time is short, the prognosis is poor. miR-10b positive expression is a prognostic factor of early breast invasive ductal cancer.